Christopher J. Hoimes, DO, presented the Hoosier Cancer Research Network study GU14-188 at a poster discussion session October 20 during the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany. Dr. Hoimes is sponsor-investigator of the study of neoadjuvant pembrolizumab and chemotherapy for locally advanced urothelial cancer.

See the HCRN GU14-188 poster and read the abstract here.

See coverage in UroToday:

• Article by Thenappan Chandrasekar, MD, Clinical Instructor, Thomas Jefferson University.
• Article by Jason Zhu, MD, Fellow, Division of Hematology and Oncology, Duke University.

Congratulations to Dr. Hoimes of Case Western Reserve University School of Medicine, and co-authors Costantine Albany, Clint Cary, Michael O. Koch, and Hristos Kaimakliotis of Indiana University School of Medicine; Jean Hoffman-Censits, Eduoard Trabulsi, W. Kevin Kelly, and J. Luke Godwin of Thomas Jefferson University Kimmel Cancer Center; Mark Fleming of Virginia Oncology Associates; Joel Picus of Washington University School of Medicine; Radhika Walling of Community Regional Cancer Center, Indianapolis; Matthew Cooney, Pingfu Fu, and Arial Nelson of Case Western Reserve University School of Medicine; and Krupen Patel and Cheryl Eitman of University Hospitals of Cleveland Seidman Cancer Center.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 200 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 8,000 subjects have participated in Hoosier Cancer Research Network clinical trials.